Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
Stocks · News reference
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 (FOR THE TREATMENT OF CANCER)".
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Aptevo Therapeutics Inc. (APVO)
Filed: 2026-09-03 AccNo: 0001193125-26-381098 Size: 185 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS".
https://patentcenter.uspto.gov/applications/18255342/ifw/docs